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Abstract: Background: Medication adherence after percutaneous coronary intervention (PCI) is essential
to preventing the risk of restenosis. Even though Type D personality and depression have been
known to affect medication non-adherence, their combined influence on PCI patients remains unclear.
Aim: We aimed to identify how both Type D personality and depression were associated with
medication non-adherence for 3 months after successful PCI. Methods: This prospective cohort
study included 257 PCI patients, who took 3 or more cardiac medications, at a university hospital.
We measured sociodemographic and clinical variables, Type D personality, depression, and medication
non-adherence using face-to-face interviews and medical record reviews. Results: The total prevalence
of medication non-adherence at the one- and three-month follow-ups was 14% and 16%, respectively.
At one month, the prevalence of those with a combination of Type D personality and depression
(23.4%) and depression alone (24%) was significantly higher than other groups. At three months,
the prevalence of the Type D personality-only group (39.1%) was the highest. Type D personality
increased the risk of medication non-adherence 5.089 times at three months, while depression increased
it 2.6 times at one month. However, the risk of medication non-adherence was not increased in
patients with combined Type D personality and depression. Conclusions: Individual assessments of
Type D personality and depression are required. Therefore, psychological interventions focusing on
personality and depression are crucial. Longitudinal follow-up studies must explore the interaction
or individual impact of Type D personality and depression on medication non-adherence and other
negative outcomes.
Keywords: Type D personality; depression; medication non-adherence; percutaneous
coronary intervention
1. Introduction
Percutaneous coronary intervention (PCI), using a balloon and stent in the diseased area of the
artery, is effective in relieving symptoms such as chest pain, shortness of breath, and nausea [1].
By treating the stenotic coronary arteries, it also prevents the risk of new cardiac events and early
death in patients with cardiovascular disease [1]. Discharge from hospital is a critical time for patients
because they need to adjust their lifestyles and incorporate new medications [2].
Medication adherence is a particularly important component of self-care after PCI for effective
secondary prevention [3]. In addition, medication adherence significantly improves health outcomes,
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and has even been found to reduce total annual coronary artery disease (CAD) medical costs [2,4].
Approximately 50% of patients with cardiovascular disease display poor adherence to prescribed
medications [5,6]. According to a previous study, the percentage of patients adherent to both
antihypertensive and lipid-lowering therapy declined sharply following treatment initiation, with
44.7%, 35.9%, and 35.8% of patients adherent at 3, 6, and 12 months, respectively [7]. According to
another study, patients who were not compliant with four or more cardio-related medications had
about a three times higher risk of mortality and reinfarction rates [8].
Non-adherence to medications remains a major problem for cardiovascular patients. It leads
to poor clinical outcomes, including rehospitalization, subsequent myocardial infarction (MI), and
increased mortality in various patient settings [9]. To improve patients’ short- and long-term
medication adherence after PCI, healthcare providers need to use multiple approaches [10].
Type D personality, a type personality, is combined by social inhibition (SI, the tendency to inhibit
the expression of these emotions in social interaction) and negative affectivity (NA, the tendency to
experience the negative emotions) [11]. The Type D personality concept was originally developed
to identify cardiac patients at risk of developing emotional and interpersonal difficulties [12]. It has
been strongly associated with risk factors of poor perceived health patients in cardiac disease [11,12].
For this reason, Type D personality has been included in the European Cardiovascular Prevention
guideline since 2012 [13]. The prevalence of Type D personality among CAD is around 20–50%, making
it a factor that should not be ignored [14]. Type D personality has been strongly linked to both physical
and psychological morbidity and survival after the onset of conditions related to cardiovascular
disease [15]. Those with Type D personality showed an increased risk of major adverse cardiac events
such as MI, PCI, and coronary artery bypass graft at 15 months post-PCI [16].
The prevalence of depression as a mood status in patients with CAD ranges from 25–50% [17].
Depression after a coronary artery bypass graft was a predictor of higher readmission rates within
6 months and increased cardiac events and mortality [18]. Depression not only reflects episodic distress
but also a more ingrained tendency to experience distress, with the combination of distress and social
isolation predicting a poor cardiac prognosis [19].
Despite evidence of these factors’ importance in the outcomes of CAD patients, the prospective
relationship between medication non-adherence and Type D personality or/and depression has rarely
been reported [20]. Moreover, there have been debates regarding overlapping constructs between
Type D personality and depression [21,22]. One study reported that the negative affectivity dimension,
measured through the Type D Scale-14 (DS-14), and depressive symptoms are largely overlapping
constructs [22]. Conversely, most previous studies [23–26] have confirmed that Type D personality and
depression represent a different form of distress. Namely, Type D personality traits have been found to
be relatively stable over time and their combination gives rise to a general propensity to psychological
distress such as depression [23–26]. Throughout previous studies, if Type D personality might affect
depression, and if Type D personality and depression might be present together, it is likely to have a
greater negative effect on medication adherence.
To date, even though CAD has become a long term chronic condition, little is known for combined
Type D personality and depression in patients after PCI [20,27]. Therefore, to improve adherence to
medication after PCI, it is essential to investigate longitudinally the association of Type D personality
and depression with medication adherence. Therefore, this study aimed to identify the rates of
adherence to prescribed medication and then to explore the relationships between the medication
non-adherence and combined Type D personality and depression after successful PCI.
2. Methods
2.1. Study Design and Setting
This was a secondary analysis of data from a prospective cohort study demonstrating that left
ventricular ejection fraction and post-cardiac depressive symptoms have a combined effect on major
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adverse cardiac events after successful primary PCI during a 12-month follow-up in Korea [28].
We used G-power program 3.1 version to determine a sufficient sample size using an alpha of 0.05, a
power of 0.95, a medium effect size (odd ratio = 1.72) and two-tailed test. Based on the aforementioned
assumptions, the desired sample size was 286. For 3 months, 257 patients of primary study [28]
completed the follow-up. In brief, participants in this prospective study were patients with CAD at
Soonchunhyang University Hospital of Cheonan in Chunggnam, South Korea between July 2011 and
January 2012. Data were collected from July 2011 to February 2013. We chose 3 months as the minimum
follow-up period for two reasons. First, medication adherence had significantly decreased at 3 months,
to the point of affecting mortality or readmission [7,27]. Second, patients who had undergone PCI
had been diagnosed with Type D personality or depression, which might have affected medication
adherence [18,20].
Inclusion criteria included being on three or more cardiac medications (including any of the
following: antiplatelets, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor
blockers, nitrates, calcium channel blockers, antiarrhythmics, diuretics), aged 18 years or above, fluent
in Korean, and able to provide informed consent. Patients were excluded from the study if they had
cognitive impairment, known alcohol or illicit drug use, or a physical or psychological disability
inhibiting communication. At baseline, patients completed measures of Type D personality and
depression and provided demographic characteristics. At 1 and 3 months, patients completed a
self-reported measure of medication adherence via a face-to-face interview at the outpatient clinic.
2.2. Measures
2.2.1. Sociodemographic and Clinical Variables
Based on previous studies, we selected sociodemographic and clinical variables that could
cause medication non-adherence [27,29]. The baseline sociodemographic variables considered for
this study were age, sex, educational level, marital status, religion, income, job, medical insurance,
exercise, smoking, and alcohol consumption. The clinical variables considered were medical diagnosis,
type of PCI (balloon angioplasty or stenting), and patient history obtained from medical records
and interviews.
2.2.2. Medication Adherence
Medication adherence was measured at the 1- and 3-month follow-up hospital visits using
the Morisky Medication Adherence Scale-8 (MMAS-8) developed and translated Korean language
version by Morisky, Ang, Krousel-Wood, and Ward [30–32]. The MMAS-8 was designed to facilitate
identification of barriers to and behaviors associated with adherence to hypertensive medication.
It is a self-report questionnaire with 8 questions (items). Medication non-adherence is detected by
an MMAS-8 score <6 and medication adherence is detected by an MMAS-8 score ≥6. Cronbach’s α for
the MMAS-8 was 0.83. In this study, Cronbach’s α was 0.58.
2.2.3. Type D Personality
For Type D personality, the DS-14 developed by Denollet [33] was used. We adopted the validated
Korean version of the DS-14 [34]. The Type D Scale measures two stable personality traits, that is
negative affectivity (7 items) and social inhibition (7 items). Items are rated on a scale from 0 (false)
to 4 (true). Respondents scoring 10 or higher on both subscales are classified as having Type D
personality [33]. In this study, Cronbach’s α for the scale was 0.95.
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2.2.4. Depression
The Patient Health Questionnaire (PHQ-9) is a 9-item self-reported questionnaire designed to
evaluate the presence of depressive symptoms over the prior two weeks [35]. In this study, we adopted
the Korean version of the PHQ-9 standardized by Choi et al. [36]. Developed by Spitzer, Kroenke, and
Williams [37] for the purpose of major depression diagnosis, the items of the PHQ-9 are rated on a
scale of 0 to 3, with higher scores reflecting greater depressive symptoms. PHQ-9 scores of 0 to 4, 5 to
9, 10 to 19, and 20 to 27 reflect no, mild, moderate, and severe symptoms, respectively. In this study,
we set the cutoff score for the depression group at a PHQ-9 score of 5 or more [36] and Cronbach’s α
for the scale was 0.84.
2.3. Statistical Analysis
All analyses were undertaken using SPSS Version 23 (IBM Corporation, Armonk, NY, USA).
p values < 0.05 were considered statistically significant. Categorical data were presented as percentages
and continuous data as mean (SD). Differences between continuous variables were assessed using a
t-test, and the x2 test (or Fisher’s exact test when appropriate) was used for categorical variables.
To measure medication adherence, we used a repeated measures analysis of variance (ANOVA)
and a one-way ANOVA performed by combined Type D personality and depression groups. Univariate
and multivariate logistic regression analysis was conducted with medication adherence at 1 and
3 months as the dependent variable. We adjusted for age, sex (male = 1, female = 0), educational level
(low = 1, high = 0), exercise (no = 1, yes = 0), and perceived health status (low = 1, high = 0).
2.4. Ethical Considerations
The investigation conforms to the principles outlined in the Declaration of Helsinki. Ethical
approval for secondary analysis was granted by the Institutional Review Board of Gachon University
in May 2018 (IRB No.1044396-201804-HR-087-01). Patients were given an information sheet about the
study by cardiology staff who would normally be involved in their care. If they wished to participate,
a meeting was set up with a researcher where further information about the study was provided and
written informed consent was obtained.
3. Results
3.1. Patients’ Characteristics at Baseline
A total of 257 patients who underwent PCI were included in this study (Table 1). The total
prevalence of Type D personality and depression was 19% and 28% in patients with CAD,
respectively. The breakdown was as follows: 162 (63%) participants in the non-Type D personality and
non-depression group; 23 (9%) in the Type D personality-only group; 47 (18%) in the depression-only
group; and 25 (10%) in the Type D personality and depression group. The average age of participants
was 62.32 ± 10.49 years. More than half the patients were male. At 82.6%, the proportion of males
was the highest in the Type D personality-only group (p = 0.044). The lowest educational level was
observed in the combined Type D personality and depression group (p = 0.001). At 24%, the proportion
of patients who exercised (p = 0.010) was the lowest in the Type D personality and depression group.
Among clinical variables, 80.5% of the participants were diagnosed with unstable angina and
19.5% with acute MI. The group with combined Type D personality and depression showed the lowest
percentage of perceived good health status (p = 0.010).
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Table 1. Baseline characteristics by Type D personality and depression groups.
Characteristics
N (%)
p
Total
(n = 257)
Non-Type D
Personality and
Non-Depression
(n = 162)
Type D
Personality
Only
(n = 23)
Depression
Only
(n= 47)
Type D
Personality and
Depression
(n = 25)
Sociodemographic variables
Age, mean (SD) 62.32 (10.49) 62.09 (10.90) 59.43 (10.46) 64.04 (10.19) 63.20 (7.98) 0.355
Sex * male 173 (67.3) 114 (70.4) 19 (82.6) 25 (53.2) 15 (60.0) 0.044
female 84 (32.7) 48 (29.6) 4 (17.4) 22 (46.8) 10 (40.0)
Education level * low 160 (62.3) 89 (54.9) 14 (60.9) 33 (70.2) 24 (96.0) 0.001
high 97 (37.7) 73 (45.1) 9 (39.1) 14 (46.8) 1 (4.0)
Spouse, yes 206 (80.2) 136 (84.0) 18 (78.3) 33 (70.2) 19 (76.0) 0.194
Monthly income < 1,000,000 (KR
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Monthly income <1,000,000 (  ₩) 126 (49.0) 81 (50.0) 7 (30.4) 22 (46.8) 16 (64.0) 0.134 
Job, no 121 (47.1) 77 (47.5) 6 (26.1) 24 (51.1) 14 (56.0) 0.159 
Health insurance *, yes 254 (98.8) 161 (99.4) 23 (100.0) 46 (97.9) 24 (96.0) 0.415 
Exercise, yes 136 (52.9) 95 (58.6) 13 (56.5) 22 (46.8) 6 (24.0) 0.010 
Current smoking, yes 58 (22.6) 36 (22.2) 6 (26.1) 10 (21.3) 6 (24.0) 0.969 
Alcohol drinking, yes 76 (29.6) 53 (32.7) 7 (30.4) 11 (23.4) 5 (20.0) 0.434 
Clinical variables       
Diagnosis unstable angina 207 (80.5) 133 (81.2) 18 (78.3) 37 (78.7) 19 (76.0) 
0.860 AMI 50 (19.5) 29 (17.9) 5 (21.7) 10 (21.3) 6 (24.0) 
Hypertension, yes 133 (51.8) 87 (53.7) 9 (39.1) 22 (46.8) 15 (60.0) 0.414 
Diabetes, yes 88 (34.2) 52 (32.1) 6 (26.1) 23 (48.9) 7 (28.0) 0.114 
Hyperlipidemia, yes * 14 (5.4) 6 (3.7) 2 (8.7) 4 (8.5) 2 (8.0) 0.453 
Perceived health status, good * 222 (86.4) 147 (90.7) 21 (91.3) 36 (76.6) 18 (72.0) 0.010 
* Fisher’s exact test; AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; M, month. 
3.2. Patterns of Medication Adherence at 1- and 3-Month Follow-Ups 
We classified medication non-adherence as a score of <6; the frequency by baseline Type D 
personality and depression at 1- and 3-month follow-ups is demonstrated in Table 2. The total 
prevalence of medication non-adherence at the 1- and 3-month follow-ups was 14% and 16% 
respectively. The baseline Type D personality and depression and depression-only groups displayed 
significantly high percentages (23.4% and 24%, respectively) of medication non-adherence at 1 month 
(p = 0.049). The Type D personality-only group displayed the highest (39.1%) medication non-
adherence at the 3-month follow-up (p = 0.013). 
Table 2. Frequency of medication non-adherence by Type D personality and depression groups at baseline. 
Medication Non-Adherence, Yes 
(a Score of <6) 
N (%) 
p Total 
(n = 257) 
Non-Type D 
and Non-
Depression 
(n = 162) 
Type D 
Personality 
Only 
(n = 23) 
Depression 
Only 
(n = 47) 
Type D and 
Depression 
(n = 25) 
One month follow-up * 36 (14.0) 17 (10.5) 2 (8.7) 11 (23.4) 6 (24.0) 0.049 
Three month follow-up * 41 (16.0) 20 (12.3) 9 (39.1) 8 (17.0) 4 (16.0) 0.013 
* Fisher’s exact test; The MMAS (8-item) content, name, and trademarks are protected by US copyright 
and trademark laws. Permission for use of the scale and its coding is required. A license agreement is 
available from Donald E. Morisky, ScD, ScM, MSPH, 14725 NE 20th St Bellevue, WA 98007, USA; 
dmorisky@gmail.com. 
We used repeated measures ANOVA for mean comparisons of medication adherence among 
the 4 groups, presented in Table 3. Medication adherence revealed statistically significant interactions 
by times and groups (p = 0.004). Medication adherence demonstrated statistically significant 
differences among the 4 groups (p = 0.025). Especially, at a mean of 6.49, medication adherence was 
significantly lower in the depression group as compared to the non-Type D personality and non-
depression group at 1 month (F = 3.638, p = 0.013). At 3 months, with a mean of 5.96, medication 
adherence was significantly lower in the Type D personality group compared to the non-Type D 
personality and non-depression group (F = 3.688, p = 0.013). 
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3.2. Patterns of Medication Adherence at 1- and 3-Month Follow-Ups
e classified medication non-adherence as a score of <6; the frequency by baseline Type D
personality and depression at 1- and 3-month follow-ups is demonstrated in Table 2. The total
prevalence of medication non-adherence at the 1- and 3-month follow-ups was 14% and 16% respectively.
The baseline Type D personality and depression and depression-only groups displayed significantly
high percentages (23.4% and 24%, respectively) of medication non-adherence at 1 month (p = 0.049).
The Type D personality-only group displayed the highest (39.1%) medication non-adherence at the
3-month follow-up (p = 0.013).
Table 2. Frequency of medication non-adherence by Type D personality and depression groups
at baseline.
Medication Non-Adherence, Yes
(a Score of <6)
N (%)
pTotal
(n = 257)
Non-Type D and
Non-Depression
(n = 162)
Type D
Personality
Only
(n = 23)
Depression
Only
(n = 47)
Type D and
Depression
(n = 25)
One month follow-up * 36 (14.0) 17 (10.5) 2 (8.7) 11 (23.4) 6 (24.0) 0.049
Three month follo -up * 41 (16.0) 20 (12.3) 9 (39.1) 8 (17.0) 4 (16.0) 0.013
* Fisher’s exact test; The MMAS (8-item) content, name, and trademarks are protected by US copyright and
trademark laws. Per ission for use of the scale and its coding is required. A license agreement is available from
Donald E. Morisky, ScD, ScM, MSPH, 14725 NE 20th St Bellevue, WA 98007, USA; dmorisky@gmail.com.
We used peated me sures ANOVA for m an omparisons of medicat o adherence am g the
4 group , presented in Table 3. Medication adherence rev aled statistically significant interactions by
t mes and groups (p = 0.004). Medication adh rence demonstrated statistically significant differences
among the 4 groups (p = 0.025). Especially, t a mean of 6.49, medication adh rence was significantly
lower in the depression group as compared to the non-Type D personality and non-depression group at
1 month (F = 3.638, p = 0.013). At 3 months, with a mean of 5.96, medication adherence was significantly
lower in the Type D personality group compared to the non-Type D personality and non-depression
group (F = 3.688, p = 0.013).
Int. J. Environ. Res. Public Health 2018, 15, 2226 6 of 11
Table 3. Mean score for medication adherence by Type D personality and depression at baseline.
Variables
Mean (SD)
F p
1 Month 3 Months
Non-Type D personality and non-depression 7.09 (1.14) 6.95 (1.34) Time 0.559 0.455
Type D personality only 6.96 (0.98) 5.96 (1.72) * Group 3.160 0.025
Depression only 6.49 (1.52) * 6.83 (1.34) Time * Group 4.501 0.004
Type D personality and depression 6.56 (1.36) 6.96 (1.06)
F 3.638 3.688
p 0.013 0.013
Compared with normal group * p < 0.05.
3.3. Association between Medication Non-Adherence at Follow-Up and Type D Personality and Depression
at Baseline
The relationships between low medication adherence and combined Type D personality and
depression are shown in Table 4. Odds ratios (ORs) were calculated by unadjusted and adjusted
logistic regression with all significant variables—age, sex, education, exercise, and perceived health
status—among the 4 groups.
Table 4. Odds ratios (OR) for the association with medication non-adherence by Type D personality
and depression at baseline.
Variables
Unadjusted Adjusted
OR (95% CI) OR (95% CI)
1 Month 3 Months 1 Month 3 Months
Non-Type D personality and non-depression 1 1 1 1
Type D personality only 0.812 (0.175–3.770) 4.564 (1.749–11.913) * 0.773 (0.164–3.640) 5.089 (1.881–13.771) *
Depression only 2.606 (1.123–6.047) * 1.456 (0.596–3.558) 2.605 (1.083–6.266) * 1.472 (0.584–3.713)
Type D personality and depression 2.693 (0.946–7.669) 1.352 (0.421–4.345) 2.294 (0.734–7.167) 1.614 (0.461–5.654)
* p < 0.05; OR, odds ratio; CI, confidence interval; Adjusted for age, sex (male = 1, female = 0), education (low = 1,
high = 0), exercise (yes = 0, no = 1), perceived health status (low = 1, high = 0).
At 1 month, the depression-only group’s medication non-adherence rate was 2.639 times higher
(95% confidence interval (CI) 1.170–5.953) than that of the reference group, which was composed
of individuals with non-Type D personality and no depression. After adjustment, the medication
non-adherence rate was 2.605 times higher (95% CI 1.083–6.266) than that of the reference group.
At 3 months, the Type D personality group had a low medication adherence rate that was
4.564 times higher (95% CI 1.749–11.913] than that of the reference group. After adjustment, the low
medication adherence rate was 5.089 times higher (95% CI 1.881–13.771) than that of the reference group.
4. Discussion
Medication adherence after PCI is a crucial factor to prevent major adverse outcomes such as
rehospitalization and mortality [2–4]. Recently, Type D personality and depression have been reported
as independent predictors to improve health outcomes including medication adherence, quality of life,
and survival rates in patients with cardiovascular disease [4,15,38]. The primary aim of this study was to
investigate how combined Type D personality and depression affects medication adherence in patients
after successful PCI. Our main findings showed that combined, these variables had a negative influence
on medication adherence in patients after PCI. Also, we found higher rates of medication non-adherence
in alone or combined Type D personality and depression groups than in the normal group.
With respect to rates of medication adherence, the MMAS-8 cut-off to identify medication
non-adherence was 6 [28–30]. In this study, the total prevalence of medication non-adherence was
around 14% at 1 month and 16% at 3 months. Compared to previous studies [27,39], the total
prevalence of medication non-adherence was higher in our study. In acute MI patients treated with
PCI at 6 weeks, early medication non-adherence, reflected by a score of <6, was 4% [27] and in
an intervention study using administration timing simplification protocol in cardiovascular disease
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patients in Korea, MMAS scores of <6 were 6–9% at baseline [39]. Internationally, however, medication
non-adherence rates determined by using the MMAS-8 varied from 14.2–54% [40–42]. The reasons for
this difference might be variations in healthcare utilization or medical services in each country, and
perhaps even the differences in the background characteristics of the subjects [39,40]. Even though
medication adherence should be consistent, it rapidly decreased after discharge [7]. Previously, many
cross-sectional studies have been conducted to determine the various factors affecting medication
adherence [29,39,40]. When we compared with rates of medication non-adherence by combined Type D
personality and depression, there were different results due to different measurement periods. Patients
with a combination of Type D personality and depression and those with only depression after PCI
showed a higher prevalence of medication non-adherence at 1 month (23–24%), and those with Type D
personality showed a higher prevalence (39.1%) at 3 months compared to other patients. Our findings
on medication non-adherence in patients with Type D personality are consistent with those of similar
studies. In these studies, subjects with Type D personality, defined as the trait-like combination of high
levels of NA and SI, were more likely to have poor medication adherence than those with non-Type D
personality [15,43]. In addition, depression is an important risk factor for impaired health status in
chronic CAD [44] and is associated with medication non-adherence in patients with heart disease.
Most importantly, in the present study, medication non-adherence at 1 month was significantly
affected only by depression and at 3 months only by Type D personality. After adjusted variables
consistent with those of previous studies, such as males, low educational levels, limited exercise, and
low perceived good health status, we measured the OR of medication non-adherence. For 1 month
after discharge following PCI in this study, patients with depression were 2.6 times more likely to
fail to take the medication than the normal group, and at 3 months, 5.1 times higher than the Type D
personality group. These results were consistent with previous medication adherence studies about
Type D personality and depression. In short, Type D personality alone was a significant predictor
of poor medication adherence at 3 or 6 months after discharge [15,43]. Medication non-adherence in
depressed patients was approximately 1.8–2.3 times higher than in non-depressed patients [38,40].
According to previous studies, many patients might develop depression during or after the
diagnosis and treatment of diseases of the heart as a vital organ associated with life [45]. Those with
depression could return to their normal mood state in 3 months of non-pharmacological treatment or
usual care [45]. In a previous study, from Type D personality was a particularly significant factor in
individual differences in risk, and it did not change with time [33]. On the contrary, another previous
study reported that Type D personality before and after cardiac surgery could change in nearly 60% of
patients [46]. The reasons for the varying relationship between Type D personality and medication
adherence from month to month need to be identified in the future.
This present study is meaningful in that it is the first cohort study to examine the combined
impact of Type D personality and depression on medication non-adherence during a 3-month follow-up
period among PCI patients. However, there was no statistical significance in the relationship between
medication non-adherence and combined Type D personality and depression in our study. According to
previous studies on cardiovascular disease, Type D personality is highly associated with depression [47]
and Type D personality and depression are associated with lower health-related quality of life [19].
Therefore, patients who have both Type D personality and depression could require more complex
treatments [20,48].
In the present study, we chose a minimum of one- and three-month follow-up periods to identify
medication adherence for two reasons: first, a one-month follow-up for medication adherence is a
meaningful point in preventing short-term readmissions (e.g., 30-day readmission) after PCI treatment [49];
second, three months is the shortest period to meaningfully measure medication adherence, especially
now that prescriptions with 90-day supplies are common. Based on the previous study, the percentage
of the medication adherence declined rapidly following treatment initiation, with less than 45% of the
medication adherence at three months [7]. In addition, patients had significantly better rates of adherence
to medication at six weeks if they had first follow-up appointments made prior to discharge [27,50].
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This study had some limitations. First, it was based on a small convenience sample, with small
numbers of patients with CAD in each group. In future studies, it is necessary to increase the number
of samples in conjunction with numerous hospitals in order to obtain many subjects with CAD.
Second, the fact that measurements of depression, Type D personality, and medication adherence
were self-reported is a big limitation because the findings might underestimate or overestimate the
actual rates. Third, we measured Type D personality and depression at baseline with 4 groups. As the
prevalence of patients with Type D personality or depression could change at various time points
after discharge, regular screening for Type D personality and depression is needed to identify their
association with medication non-adherence. Fourth, in this study Cronbach’s α of MMAS-8 was 0.58
and indicated little higher than a minimally accepted level as low as 0.50. As known, the MMAS-8 had
reported various value of Cronbach’s α from 0.54 to 0.83 in previous studies [30,51–56]. This problem
might be related with patients’ characteristics in this study. Namely, our participants were relatively
older and have a lower level of education. As a result, self-reported MMAS-8 needs to be carefully
explained and measured with elderly patients in future studies. Furthermore, subjective measures
including self-reporting, healthcare professional assessments and objective measures such as pill
counts and biochemical tests will have advantages and should be used in combination [57].
5. Conclusions
Our main findings showed that individual Type D personality and depression were risk factors for
medication non-adherence in patients who underwent PCI. Therefore, screening for Type D personality
and depression at baseline may be useful strategies to improve medication adherence in patients who
undergo PCI. Furthermore, nurses should consider integrative person-centered approaches for patients
with CAD with a focus on identifying meaningful subgroups by Type D personality and depression.
Author Contributions: Conceptualization, Y.-J.S., B.-H.K.; Methodology, Y.-J.S., B.-H.K., and K.L.; Formal
Analysis, Y.-J.S., B.-H.K.; Data Curation, Y.-J.S., B.-H.K., and K.L.; Writing-Original Draft Preparation, Y.-J.S.,
B.-H.K.; Writing–Review & Editing, Y.-J.S., K.L., D.E.M., and B.-H.K.
Funding: This research received no external funding.
Acknowledgments: The MMAS (8-item) content, name, and trademarks are protected by US copyright and
trademark laws. Permission for use of the scale and its coding is required. A license agreement is available
from Donald E. Morisky, ScD, ScM, MSPH, 14725 NE 20th St Bellevue, WA 98007, USA; dmorisky@gmail.com.
The authors have obtained the permission to use 8-item Morisky Medication Adherence Scale.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Windecker, S.; Kolh, P.; Alfonso, F.; Collet, J.-P.; Cremer, J.; Falk, V.; Filippatos, G.; Hamm, C.; Head, S.J.;
Jüni, P.; et al. 2014 ESC/EACTS Guidelines on myocardial revascularization The task force on myocardial
revascularization of the European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of
Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014, 35, 2541–2619. [CrossRef] [PubMed]
2. Osterberg, L.; Blaschke, T. Adherence to medication. N. Engl. J. Med. 2005, 353, 487–497. [CrossRef] [PubMed]
3. Son, Y.J.; Kim, S.H.; Park, J.H. Role of depressive symptoms and self-efficacy of medication adherence in
Korean patients after successful percutaneous coronary intervention. Int. J. Nurs. Pract. 2014, 20, 564–572.
[CrossRef] [PubMed]
4. Bitton, A.; Choudhry, N.K.; Matlin, O.S.; Swanton, K.; Shrank, W.H. The impact of medication adherence
on coronary artery disease costs and outcomes: A systematic review. Am. J. Med. 2013, 126, 357e7–357e27.
[CrossRef] [PubMed]
5. Rushworth, G.F.; Cunningham, S.; Mort, A.; Rudd, I.; Leslie, S.J. Patient-specific factors relating to medication
adherence in a post-percutaneous coronary intervention cohort. Int. J. Pharm. Pract. 2012, 20, 226–237.
[CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 2226 9 of 11
6. Kronish, I.M.; Ye, S. Adherence to cardiovascular medications: Lessons learned and future directions.
Prog. Cardiovasc. Dis. 2013, 55, 590–600. [CrossRef] [PubMed]
7. Chapman, R.H.; Benner, J.S.; Petrilla, A.A.; Tierce, J.C.; Collins, S.R.; Battleman, D.S.; Schwartz, J.S. Predictors
of adherence with antihypertensive and lipid-lowering therapy. Arch. Intern. Med. 2005, 165, 1147–1152.
[CrossRef] [PubMed]
8. Amin, A.P.; Mukhopadhyay, E.; Nathan, S.; Napan, S.; Kelly, R.F. Association of medical noncompliance and
long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. Transl. Res.
2009, 154, 78–89. [CrossRef] [PubMed]
9. Fallis, B.A.; Dhalla, I.A.; Klemensberg, J.; Bell, C.M. Primary medication non-adherence after discharge from
a general internal medicine service. PLoS ONE 2013, 8, e61735. [CrossRef] [PubMed]
10. Baroletti, S.; Dell’Orfano, H. Medication adherence in cardiovascular disease. Circulation 2010, 121, 1455–1458.
[CrossRef] [PubMed]
11. Denollet, J. Personality and coronary heart disease: The Type-D Scale-16 (DS16). Ann. Behav. Med. 1998, 20,
209–215. [CrossRef] [PubMed]
12. Denollet, J.; Vaes, J.; Brutsaert, D.L. Inadequate response to treatment in coronary heart disease: Adverse
effects of type D personality and younger age on 5-year prognosis and quality of life. Circulation. 2000, 102,
630–635. [CrossRef] [PubMed]
13. Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; Cooney, M.T.; Corrà, U.;
Cosyns, B.; Deaton, C.; et al. 2016 European Guidelines on cardiovascular disease prevention in clinical
practice: The sixth joint task force of the European Society of Cardiology and other societies on cardiovascular
disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)
Developed with the special contribution of the European Association for Cardiovascular Prevention &
Rehabilitation (EACPR). Eur. Heart. J. 2016, 37, 2315–2381. [CrossRef] [PubMed]
14. Kupper, N.; Pedersen, S.S.; Höfer, S.; Saner, H.; Oldridge, N.; Denollet, J. Cross-cultural analysis of Type
D (distressed) personality in 6222 patients with ischemic heart disease: A study from the International
HeartQoL Project. Int. J. Cardiol. 2013, 166, 327–333. [CrossRef] [PubMed]
15. Molloy, G.J.; Randall, G.; Wikman, A.; Perkins-Porras, L.; Messerli-Burgy, N.; Steptoe, A. Type D personality,
self-efficacy, and medication adherence following an acute coronary syndrome. Psychosom. Med. 2012, 74,
100–106. [CrossRef] [PubMed]
16. Denollet, J.; Pedersen, S.S.; Ong, A.T.L.; Erdman, R.A.M.; Serruys, P.W.; van Domburg, R.T. Social inhibition
modulates the effect of negative emotions on cardiac prognosis following percutaneous coronary intervention
in the drug-eluting stent era. Eur. Heart J. 2006, 27, 171–177. [CrossRef] [PubMed]
17. Parakh, K.; Thombs, B.D.; Fauerbach, J.A.; Bush, D.E.; Ziegelstein, R.C. Effect of depression on late (8 years)
mortality after myocardial infarction. Am. J. Cardiol. 2008, 101, 602–606. [CrossRef] [PubMed]
18. Oxlad, M.; Stubberfield, J.; Stuklis, R.; Edwards, J.; Wade, T.D. Psychological risk factors for cardiac-related
hospital readmission within 6 months of coronary artery bypass graft surgery. J. Psychosom. Res. 2006, 61,
775–781. [CrossRef] [PubMed]
19. Staniute, M.; Brozaitiene, J.; Burkauskas, J.; Kazukauskiene, N.; Mickuviene, N.; Bunevicius, R. Type D
personality, mental distress, social support and health-related quality of life in coronary artery disease
patients with heart failure: A longitudinal observational study. Health Qual. Life Outcomes 2015, 13, 1.
[CrossRef] [PubMed]
20. AL-Qezweny, M.N.A.; Utens, E.M.W.J.; Dulfer, K.; Hazemeijer, B.A.F.; van Geuns, R.-J.; Daemen, J.; van
Domburg, R. The association between type D personality, and depression and anxiety ten years after PCI.
Neth. Heart J. 2016, 24, 538–543. [CrossRef] [PubMed]
21. Lespérance, F.; Frasure-Smith, N. Negative emotions and coronary heart disease: Getting to the heart of the
matter. Lancet 1996, 347, 414–415. [CrossRef]
22. Paolo, O.; Chiara, D.P.; Matteo, T.; Diego, A.; Carlo, M. DS14 is more likely to measure depression rather
than a personality disposition in patients with acute coronary syndrome. Scand. J. Psychol. 2015, 56, 685–692.
[CrossRef]
23. Denollet, J.; Pedersen, S.S. Prognostic value of type D personality compared with depressive symptoms.
Arch. Intern. Med. 2008, 168, 431–432. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 2226 10 of 11
24. Vukovic, O.; Lecic Tosevski, D.; Jasovic-Gasic, M.; Damjanovic, A.; Zebic, M.; Britvic, D.; Stepanovic, J.;
Djordjevic-Dikic, A.; Beleslin, B.; Ostojic, M. Type D personality in patients with coronary artery disease.
Psychiatr. Danub. 2014, 26, 46–51. [PubMed]
25. Pelle, A.J.; Denollet, J.; Zwisler, A.D.; Pedersen, S.S. Overlap and distinctiveness of psychological risk factors
in patients with ischemic heart disease and chronic heart failure: Are we there yet? J. Affect. Disord. 2009,
113, 150–156. [CrossRef] [PubMed]
26. Kelpis, T.G.; Anastasiadis, K.; Nimatoudis, I.; Kelpi, M.G.; Hadjimiltiades, S.; Papakonstantinou, C.
Prevalence of “distressed” personality in patients with coronary artery disease and its correlation with
morbidity after coronary surgery. Hellenic. J. Cardiol. 2013, 54, 362–367. [PubMed]
27. Mathews, R.; Peterson, E.D.; Honeycutt, E.; Chin, C.T.; Effron, M.B.; Zettler, M.; Fonarow, G.C.;
Henry, T.D.; Wang, T.Y. Early medication nonadherence after acute myocardial infarction. Insights into
actionable opportunities from the treatment with ADP receptor inhibitors: Longitudinal assessment of
treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Cirs. Cardiovasc.
Qual. Outcomes 2015, 8, 347–356. [CrossRef]
28. Yu, H.Y.; Park, Y.S.; Son, Y. Combined effect of left ventricular ejection fraction and post-cardiac depressive
symptoms on major adverse cardiac events after successful primary percutaneous coronary intervention: A
12-month follow-up. Eur. J. Cardiovasc. Nurs. 2016, 16, 37–45. [CrossRef] [PubMed]
29. Kripalani, S.; Goggins, K.; Nwosu, S.; Schildcrout, J.; Mixon, A.S.; McNaughton, C.; McDougald Scott, A.M.;
Wallston, K.A. Medication nonadherence before hospitalization for acute cardiac events. J. Health Commun.
2015, 20, 34–42. [CrossRef] [PubMed]
30. Morisky, D.E.; Ang, A.; Krousel-Wood, M.; Ward, H.J. Predictive validity of a medication adherence measure
in an outpatient setting. J. Clin. Hypertens. 2008, 10, 348–354. [CrossRef]
31. Morisky, D.E.; DiMatteo, M.R. Improving the measurement of self-reported medication nonadherence:
Response to authors. J. Clin. Epidemiol. 2011, 64, 255–263. [CrossRef] [PubMed]
32. Berlowitz, D.R.; Foy, C.G.; Kazis, L.E.; Bolin, L.P.; Conroy, M.B.; Fitzpatrick, P.; Gure, T.R.; Kimmel, P.L.;
Kirchner, K.; Morisky, D.E.; et al. Effect of intensive blood-pressure treatment on patient-reported outcomes.
N. Engl. J. Med. 2017, 377, 733–744. [CrossRef] [PubMed]
33. Denollet, J. DS14: Standard assessment of negative affectivity, social inhibition, and type D personality.
Psychosom. Med. 2005, 67, 89–97. [CrossRef] [PubMed]
34. Lim, H.E.; Lee, M.S.; Ko, Y.H.; Park, Y.M.; Joe, S.H.; Kim, Y.K.; Han, C.; Lee, H.Y.; Pedersen, S.S.; Denollet, J.
Assessment of the type D personality construct in the Korean population: A validation study of the Korean
DS14. J. Korean. Med. Sci. 2011, 26, 116–123. [CrossRef] [PubMed]
35. Kroenke, K.; Spitzer, R.L.; Williams, J.B.W. The PHQ-9: Validity of a brief depression severity measure. J. Gen.
Intern. Med. 2001, 16, 606–613. [CrossRef] [PubMed]
36. Choi, H.S.; Choi, J.H.; Ko, H.J.; Park, K.H.; Joo, K.J.; Ga, H.; Kim, S.R. Standardization of the Korean version
of patient health questionnaire-9 as a screening instrument for major depressive disorder. J. Korean Acad.
Fam. Med. 2007, 28, 114–119.
37. Spitzer, R.L.; Kroenke, K.; Williams, J.B. Validation and utility of a self-report version of PRIME-MD: The
PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA
1999, 282, 1737–1744. [CrossRef] [PubMed]
38. Krousel-Wood, M.; Joyce, C.; Holt, E.; Muntner, P.; Webber, L.S.; Morisky, D.E.; Frohlich, E.D.; Re, R.N.
Predictors of decline in medication adherence: Results from the cohort study of medication adherence among
older adults. Hypertension 2011, 58, 804–810. [CrossRef] [PubMed]
39. Jung, S.H.; Lee, O.S.; Kim, H.S.; Park, C.S.; Lee, H.J.; Kwon, K.H.; Lee, H.Y. Medication adherence
improvement by using administration timing simplification protocol (ATSP) in cardiovascular disease
patients. J. Atheroscler. Thromb. 2017, 24, 841–852. [CrossRef] [PubMed]
40. Holt, E.; Joyce, C.; Dornelles, A.; Morisky, D.; Webber, L.S.; Muntner, P.; Krousel-Wood, M. Sex differences in
barriers to antihypertensive medication adherence: Findings from the cohort study of medication adherence
among older adults. J. Am. Geriatr. Soc. 2013, 61, 558–564. [CrossRef] [PubMed]
41. de Oliveira-Filho, A.D.; Morisky, D.E.; Neves, S.J.; Costa, F.A.; de Lyra, D.P., Jr. The 8-item Morisky
Medication Adherence Scale: Validation of a Brazilian–Portuguese version in hypertensive adults. Res. Social.
Adm. Pharm. 2014, 10, 554–561. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2018, 15, 2226 11 of 11
42. Moharamzad, Y.; Saadat, H.; Shahraki, B.N.; Rai, A.; Saadat, Z.; Aerab-Sheibani, H.; Naghizadeh, M.M.;
Morisky, D.E. Validation of the Persian version of the 8-item Morisky Medication Adherence Scale (MMAS-8)
in Iranian hypertensive patients. Glob. J. Health Sci. 2015, 7, 173–183. [CrossRef] [PubMed]
43. Williams, L.; O’Connor, R.C.; Grubb, N.; O’Carroll, R. Type D personality predicts poor medication adherence
in myocardial infarction patients. Psychol. Health 2011, 26, 703–712. [CrossRef] [PubMed]
44. Mols, F.; Martens, E.J.; Denollet, J. Type D personality and depressive symptoms are independent predictors
of impaired health status following acute myocardial infarction. Heart 2010, 96, 30–35. [CrossRef] [PubMed]
45. Freedland, K.E.; Skala, J.A.; Carney, R.M.; Rubin, E.H.; Lustman, P.J.; Davila-Roman, V.G.; Steinmeyer, B.C.;
Hoque, C.W., Jr. Treatment of depression after coronary artery bypass surgery: A randomized controlled
trial. Arch. Gen. Psychiatry 2009, 66, 387–396. [CrossRef] [PubMed]
46. Dannemann, S.; Matschke, K.; Einsle, F.; Smucker, M.R.; Zimmermann, K.; Joraschky, P.; Weidner, K.;
Köllner, V. Is type-D a stable construct? An examination of type-D personality in patients before and after
cardiac surgery. J. Psychosom. Res. 2010, 69, 101–109. [CrossRef] [PubMed]
47. Van Dooren, F.E.; Verhey, F.R.; Pouwer, F.; Schalkwijk, C.G.; Sep, S.J.; Stehouwer, C.D.; Henry, R.M.;
Dagnelie, P.C.; Schaper, N.C.; van der Kallen, C.J.; et al. Association of Type D personality with increased
vulnerability to depression: Is there a role for inflammation or endothelial dysfunction?—The Maastricht
Study. J. Affect. Disord. 2016, 189, 118–125. [CrossRef] [PubMed]
48. Lambertus, F.; Herrmann-Lingen, C.; Fritzsche, K.; Hamacher, S.; Hellmich, M.; Jünger, J.; Ladwig, K.-H.;
Michal, M.; Ronel, J.; Schultz, J.-H.; et al. Prevalence of mental disorders among depressed coronary patients
with and without Type D personality. Results of the multi-center SPIRR-CAD trial. Gen. Hosp. Psychiatry.
2018, 50, 69–75. [CrossRef] [PubMed]
49. Shah, M.; Patnaik, S.; Patel, B.; Arora, S.; Patel, N.; Lahewala, S.; Figueredo, V.M.; Martinez, M.W.; Jacobs, L.
The day of the week and acute heart failure admissions: Relationship with acute myocardial infarction,
30-day readmission rate and in-hospital mortality. Int. J. Cardiol. 2017, 249, 292–300. [CrossRef] [PubMed]
50. Faridi, K.F.; Peterson, E.D.; McCoy, L.A.; Thomas, L.; Enriquez, J.; Yang, T.Y. Timing of first postdischarge
follow-up and medication adherence after acute myocardial infarction. JAMA Cardiol. 2016, 1, 147–155.
[CrossRef] [PubMed]
51. Sakthong, P.; Chabunthom, R.; Charoenvisuthiwongs, R. Psychometric properties of the Thai version of the
8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Ann. Pharmacother. 2009, 43,
950–957. [CrossRef] [PubMed]
52. Al-Qazaz, H.K.; Hassali, M.A.; Shafie, A.A.; Sulaiman, S.A.; Sundram, S.; Morisky, D.E. The eight-item
Morisky Medication Adherence Scale MMAS: Translation and validation of the Malaysian version.
Diabetes. Res. Clin. Pract. 2010, 90, 216–221. [CrossRef] [PubMed]
53. Reynolds, K.; Viswanathan, H.N.; O’Maley, C.D.; Muntner, P.; Harrison, T.N.; Cheetham, T.C.; Hsu, J.W.;
Gold, D.T.; Silverman, S.; Grauer, A.; et al. Psychometric properties of the osteoporosis-specific
Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with
bisphosphonates. Ann. Pharmacother. 2012, 46, 659–670. [CrossRef] [PubMed]
54. Korb-Savoldelli, V.; Gillaizeau, F.; Pouchot, J.; Lenain, E.; Postel-Vinay, N.; Plouin, P.F.; Durieux, P.; Sabatier, B.
Validation of a French version of the 8-item Morisky Medication Adherence Scale in hypertensive adults.
J. Clin. Hypertens. 2012, 14, 429–434. [CrossRef] [PubMed]
55. Wang, Y.; Kong, M.C.; Ko, Y. Psychometric properties of the 8-item Morisky Medication Adherence Scale in
patients taking warfarin. Thromb. Haemost. 2012, 108, 789–795. [CrossRef] [PubMed]
56. Lee, W.Y.; Ahn, J.; Kim, J.H.; Hong, Y.P.; Hong, S.K.; Kim, Y.T.; Lee, S.H.; Morisky, D.E. Reliability and validity
of a self-reported measure of medication adherence in patients with type 2 diabetes mellitus in Korea. J. Int.
Med. Res. 2013, 41, 1098–1110. [CrossRef] [PubMed]
57. Lam, W.Y.; Fresco, P. Medication adherence measures: An overview. Biomed. Res. Int. 2015, 2015, 217047.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
